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Cancer stem cells (CSCs) are thought to be critical for initiation and propagation of many types of 
cancer. Because these cells are resistant to conventional therapies, they have been very difficult to 
eliminate. A study in this issue of Cancer Cell suggests that brain tumor CSCs live in a “vascular 
niche” that promotes their long-term growth and self-renewal. Disrupting this niche impairs CSC 
self-renewal and thereby significantly inhibits the growth of tumors. Targeting the unique microenvi-
ronment of CSCs may be the key to effective cancer therapy.Once upon a time, cancer was 
viewed as a homogeneous mass 
of rapidly proliferating cells, and 
therapeutics were designed to 
eliminate highly proliferative cells. 
But recent studies have suggested 
that tumor cells are heterogeneous 
with respect to proliferation and dif-
ferentiation, and that a cell’s prolif-
erative rate may be a poor indicator 
of its tumorigenic potential. In sev-
eral malignancies, the capacity to 
initiate and maintain tumor growth 
has been found to reside in a small 
population of cells called cancer 
stem cells (CSCs) (Al-Hajj et al., 
2004; Reya et al., 2001; Wicha et al., 
2006). Like normal stem cells, CSCs 
have the ability to self-renew and to 
give rise to the variety of prolifer-
ating and differentiated cells that 
make up the bulk of a tumor. Impor-
tantly, CSCs are often relatively 
quiescent and therefore may not be affected by therapies targeting rap-
idly dividing cells. Elevated expres-
sion of transporters that pump out 
chemotherapeutic agents (Donnen-
berg and Donnenberg, 2005) and an 
increased capacity to repair DNA 
damage (Bao et al., 2006a) may also 
contribute to CSCs’ ability to survive 
conventional modes of therapy.
The resistance of CSCs to conven-
tional therapies may help explain why 
such therapies often fail: although they 
may destroy the bulk of a tumor, they 
cannot prevent the surviving CSCs 
from kicking into action and regener-
ating it again (Al-Hajj et al., 2004; Reya 
et al., 2001; Wicha et al., 2006). In this 
view, effective cancer treatment will 
require targeting CSCs themselves. 
But what are the signals that regulate 
CSC survival and function, and is there 
an effective way to subvert them?
One way to identify regulators 
of CSCs is to look for analogies Cancer Cellwith normal stem cells. An impor-
tant characteristic of normal neural 
stem cells (NSCs) is that they are 
concentrated in regions that are 
rich in blood vessels, called “vas-
cular niches” (Ramirez-Castillejo et 
al., 2006; Shen et al., 2004). These 
niches are thought to shelter NSCs 
from apoptotic stimuli and allow 
them to maintain a proper balance 
between self-renewal and differenti-
ation. Endothelial cells (ECs), which 
line blood vessels, secrete factors 
that promote stem cell survival and 
self-renewal and are thought to be a 
key component of the NSC niche.
A study in this issue of Cancer Cell 
suggests that CSCs in brain tumors, 
similar to NSCs, reside in vascular 
niches, and that disrupting these 
niches may be the key to eliminating 
CSCs (Calabrese et al., 2007). By 
analyzing a large cohort of human 
brain tumors, Calabrese et al. dem- 11, January 2007 ©2007 Elsevier Inc. 
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Previewsfigure 1. Model for the Role of the Vascular niche in cancer
(A) Cancer stem cells (CSCs) reside in close proximity to blood vessels, where they receive sig-
nals that allow them to self-renew and to generate transit-amplifying cells. Transit-amplifying cells 
proliferate rapidly and make up the bulk of the tumor but cannot self-renew and only give rise to 
differentiated (postmitotic) cells. The continued generation of transit-amplifying cells from CSCs 
allows the tumor to keep growing. 
(B) Antiangiogenic therapies disrupt blood vessels, leading to disintegration of the vascular niche. 
Without this niche, CSCs cannot self-renew and instead only differentiate into transit-amplifying 
cells. As these cells exhaust themselves, the tumor gradually stops growing and involutes.
Illustration by Stan Coffman/Medmedia Solutions.onstrated that cells expressing 
markers of CSCs represent a very 
small fraction of tumor tissue and 
are frequently located close to cap-
illaries within the tumor. Moreover, 
when cultured with primary human 
endothelial cells, CSCs rapidly and 
selectively associate with these  Cancer Cell 11, January 2007 ©2007 Elcells, while the majority of tumor 
cells do not. Importantly, ECs also 
enhance the self-renewal capac-
ity of CSCs in vitro. To examine the 
consequences of this interaction for 
tumor growth in vivo, Calabrese et 
al. transplanted human medullo-
blastoma cells, with or without ECs, sevier Inc.into immunocompromised mice. In 
both cases the transplanted cells 
formed tumors. However, medul-
loblastoma cells transplanted with 
ECs grew more rapidly and formed 
much larger tumors than those 
transplanted alone. Moreover, 
tumors that were established in the 
presence of ECs contained up to 25 
times more CSCs. Thus, ECs can 
enhance the self-renewal of CSCs 
in vitro and promote the growth of 
brain tumors in vivo.
Calabrese et al. then investi-
gated whether elimination of ECs 
could prevent tumor growth. Pre-
vious studies had demonstrated 
that medulloblastomas often over-
express ERBB2, which leads to 
increased production of vascular 
endothelial growth factor (VEGF), a 
critical regulator of EC survival and 
proliferation. Consistent with a role 
for ECs in maintaining CSCs, medul-
loblastoma cells overexpressing 
ERBB2 formed tumors more rapidly 
than control cells, and these tumors 
contained a higher proportion of 
CSCs. Importantly, treatment of 
tumor-bearing mice with inhibitors 
of either ERBB2 or VEGF signaling 
depleted blood vessels and caused 
a dramatic reduction in the number 
of CSCs and in the growth rate of 
the tumor. Interestingly, these drugs 
had little effect on the proliferation 
or survival of most of the cells in the 
tumor, suggesting that they were 
specifically acting on the CSCs. 
Similar results were seen with glio-
blastoma cells, raising the possibil-
ity that inhibition of blood vessel 
growth may be an effective method 
for eliminating CSCs in many types 
of brain tumors.
The work of Calabrese et al. high-
lights the importance of the vascu-
lar microenvironment in brain tumor 
growth (see Figure 1). Their observa-
tion that cotransplantation of tumor 
cells with ECs leads to more rapid 
tumor formation raises the possi-
bility that the vascular niche might 
contribute to tumor initiation. For 
example, stem cells or progenitors 
that develop mutations within the 
vascular niche might be more likely 
to give rise to tumors than those 
outside the niche. Similarly, the 
Cancer Cell
Previewsfinding that disruption of angiogen-
esis leads to a reduction in growth 
of fully formed tumors suggests that 
the vascular niche may also be criti-
cal for tumor maintenance. Once a 
tumor is established, CSCs that find 
a vascular niche may continue to 
self-renew, while those that cannot 
may differentiate into transit-ampli-
fying cells that contribute to the bulk 
of the tumor but not to its long-term 
maintenance. Identification of the 
signals that allow ECs to regulate 
CSC self-renewal may shed light on 
precisely when and how the niche 
regulates tumorigenesis.
Interestingly, recent evidence 
suggests that the relationship 
between CSCs and the vascular 
niche may be bidirectional: just as 
the niche can support the growth 
and renewal of CSCs, CSCs may 
contribute to maintenance of the 
niche. Bao et al. (2006b) show that 
CSCs from gliomas secrete mark-
edly elevated levels of VEGF, which 
significantly increases EC migration 
and tube formation. This reciprocal 
relationship raises the question of 
how the niche itself is generated: 
are CSCs attracted to pre-existing 
blood vessels, or do they create a 
vascular network to support them-
selves? Either way, the interdepen-
dence of CSCs and ECs makes the 
vascular niche an important target 
for therapy.
Of course, the use of antiangio-
genic therapy to target cancer is 
not a new idea. But while numer-
ous studies have suggested that 
preventing the growth of new blood 
vessels can inhibit tumor growth, the 
mechanism by which this therapy 
works remains a subject of debate 
(Jain, 2001; Lin and Sessa, 2004). 
The work of Calabrese et al. sug-
gests that one mechanism by which 
antiangiogenic drugs might act is by 
disrupting a vascular niche that is 
necessary for CSC self-renewal. The 
notion that antiangiogenic therapy 
targets CSCs has important impli-cations for evaluating and optimiz-
ing the use of antiangiogenic drugs 
in cancer. For example, it is notable 
that Calabrese et al. observe that 
antiangiogenic agents have a strik-
ing effect on CSC renewal but have 
little effect on proliferation or apop-
tosis of the majority of tumor cells. 
This suggests that in evaluating 
antiangiogenic therapies, it may not 
be sufficient to look for rapid tumor 
regression or shrinkage. Rather, 
more careful examination of tumor 
morphology and functional proper-
ties of tumor cells may be required 
to determine whether a particular 
agent is having an effect.
In general, therapies that target 
CSCs may have unique properties 
compared to therapies that tar-
get the bulk of a tumor. Assuming 
that CSCs represent only a small 
proportion of the entire tumor, kill-
ing them may, in the short term, 
have little impact on the size of the 
tumor as a whole. However, over 
time the tumor would be expected 
to exhaust itself and wither away, 
because it has lost the capacity for 
long-term self-renewal. From a clini-
cal standpoint, it remains to be seen 
whether such therapies are effective 
on their own; it is possible that, for 
some cancers, continued prolifera-
tion of transit-amplifying cells that 
make up the bulk of the tumor may 
be sufficient to cause irreversible 
histological and physiological dam-
age. In that sense, it may be criti-
cal to combine CSC targeting with 
conventional agents that debulk 
the tumor. Indeed, combinations of 
antiangiogenic drugs with conven-
tional chemotherapies have proven 
to be more effective than either 
mode of therapy alone (Tozer et 
al., 2005). Finding the appropriate 
combinations of therapeutic agents 
to achieve both debulking and CSC 
elimination will be an important 
challenge in the clinic.
The theory that tumors depend 
on a small population of CSCs for Cancer Celltheir long-term growth and propa-
gation has profound implications for 
our understanding and treatment 
of cancer. But until recently, this 
theory has largely served to explain 
why conventional therapies may fail. 
The work of Calabrese et al. takes a 
critical next step, identifying unique 
properties and vulnerabilities of 
CSCs that may allow us to target 
them. Only by delving into the biol-
ogy of CSCs—both their intrinsic 
properties and their microenviron-
ment—will we find ways to prevent 
their longevity from interfering with 
our own.
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